Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced the appointment of Anne Moore, PhD, to the position of Vice President Corporate Strategy. Dr. Moore will be responsible for leading corporate strategy including communications and will be a key member of the business development team. Dr. Moore will be based in Mont-Saint-Guibert, Belgium and will report to Filippo Petti, Chief Financial Officer.
“We are extremely excited to welcome Anne to our team,” commented Mr. Petti. “Her scientific and financial background, coupled with her broad experience in the industry will bring valuable strategic insight to help guide Celyad’s future success and growth.”
“I am honored and thrilled to join Celyad at such a transformational time,” said Dr. Moore. “The Company’s autologous and allogeneic CAR-T cell therapy approaches have ground-breaking potential. In addition, the Company’s shRNA platform should help to further refine and increase persistency of such therapies. With so many powerful tools at hand, I see a great potential for the Company to develop therapies to benefit patients. I am eager to quickly get to work with Celyad’s seasoned leadership team to drive our future strategy.”
Dr. Moore brings to Celyad over 12 years of global experience in strategy consulting and investment banking. Prior to joining Celyad, Dr. Moore served as vice president of healthcare investment banking at Bryan, Garnier & Co., leading numerous equity financings and strategic engagements for clients across Europe and the United States. She also spent eight years in New York working with organizations such as Credit Suisse, Huron Consulting Group and Bionest Partners where she advised mid-sized biotech to larger pharma companies on product launches, marketing, patient services, messaging and branding. Previously, she worked in management consulting in Paris, assisting start-ups shape growth strategies and get their message across.
Anne holds a PhD in Human Genetics and Physiology from the Paris XII University and an Advanced Masters in Biotechnology Management from Toulouse Business School.